XM does not provide services to residents of the United States of America.

Tempus AI shares jump 8% in strong Nasdaq debut as US IPO market thaws



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Tempus AI shares jump 8% in strong Nasdaq debut as US IPO market thaws</title></head><body>

Adds background in paragraphs 6-10

June 14 (Reuters) -Shares of SoftBank Group-backed 9984.T Tempus AI TEM.O rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion.

The company is among the several AI-focused firms that have garnered investors' interest, thanks to the popularity of OpenAI's viral chatbot ChatGPT.

The stock opened at $40 apiece, compared with the initial public offering (IPO) price of $37.

The strong debut bodes well for other companies looking to go public, as the U.S. capital market rebounds in 2024 after a dry spell that lasted nearly two years.

Other high-profile listings this year include Chinese EV firm Zeekr ZK.N and social media platform Reddit RDDT.N, which fared well in their debuts too.

Tempus AI was founded in 2015, about a year after CEO Eric Lefkofsky found out that his wife had been diagnosed with breast cancer.

Tempus sells genomics diagnostics tests across oncology, neuropsychiatry, radiology and cardiology to clinicians and hospital systems.

The company boasts of several big investors including Alphabet's Google GOOGL.O, investment managers Franklin Templeton BEN.N and T Rowe Price TROW.O, according to PitchBook.

Tempus' customers include major drugmakers such as AstraZeneca AZN.L and GSK GSK.L. It competes with Swiss drugmaker Roche's ROG.S genomic profiling unit Foundation Medicine and cancer test maker Guardant Health GH.O.

Separately, Guardant had sued Tempus AI on Wednesday for allegedly infringing five patents related to DNA-based cancer testing.

Chicago, Illinois-based Tempus has raised $410.7 million in its IPO, after it priced its shares at the higher end of its targeted range of $35 to $37.

The offering was underwritten by a cartel of top Wall Street names such as Morgan Stanley, J.P. Morgan and Bank of America Securities, among others.



Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by Shilpi Majumdar

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.